Cargando…

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer

RATIONALE: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 ((89)Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosar, Florian, Khreish, Fadi, Marlowe, Robert J., Schaefer-Schuler, Andrea, Burgard, Caroline, Maus, Stephan, Petto, Sven, Bartholomä, Mark, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317886/
https://www.ncbi.nlm.nih.gov/pubmed/37148297
http://dx.doi.org/10.1007/s00259-023-06241-0
_version_ 1785067920319053824
author Rosar, Florian
Khreish, Fadi
Marlowe, Robert J.
Schaefer-Schuler, Andrea
Burgard, Caroline
Maus, Stephan
Petto, Sven
Bartholomä, Mark
Ezziddin, Samer
author_facet Rosar, Florian
Khreish, Fadi
Marlowe, Robert J.
Schaefer-Schuler, Andrea
Burgard, Caroline
Maus, Stephan
Petto, Sven
Bartholomä, Mark
Ezziddin, Samer
author_sort Rosar, Florian
collection PubMed
description RATIONALE: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 ((89)Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that are missed when using tracers incorporating short-lived radionuclides. MATERIALS AND METHODS: To confirm [(89)Zr]Zr-PSMA-617 positron emission tomography/computed tomography (PET/CT) detection efficacy regarding such lesions, and compare quality of 1-h, 24-h, and 48-h [(89)Zr]Zr-PSMA-617 scans, we retrospectively analyzed visual findings and PET variables reflecting lesional [(89)Zr]Zr-PSMA-617 uptake and lesion-to-background ratio. The cohort comprised 23 men with BCR post-prostatectomy, median (minimum–maximum) prostate-specific antigen (PSA) 0.54 (0.11–2.50) ng/mL, and negative [(68)Ga]Ga-PSMA-11 scans 40 ± 28 d earlier. Primary endpoints were percentages of patients with, and classifications of, suspicious lesions. RESULTS: Altogether, 18/23 patients (78%) had 36 suspicious lesions (minimum–maximum per patient: 1–4) on both 24-h and 48-h scans (n = 33 lesions) or only 48-h scans (n = 3 lesions). Only one lesion appeared on a 1-h scan. Lesions putatively represented local recurrence in 11 cases, and nodal or bone metastasis in 21 or 4 cases, respectively; 1/1 lesion was histologically confirmed as a nodal metastasis. In all 15 patients given radiotherapy based on [(89)Zr]Zr-PSMA-617 PET/CT, PSA values decreased after this treatment. Comparison of PET variables in 24-h vs 48-h scans suggested no clear superiority of either regarding radiotracer uptake, but improved lesion-to-background ratio at 48 h. CONCLUSIONS: In men with BCR and low PSA, [(89)Zr]Zr-PSMA-617 PET/CT seems effective in finding prostate malignancy not seen on [(68)Ga]Ga-PSMA-11 PET/CT. The higher detection rates and lesion-to-background ratios of 48-h scans versus 24-h scans suggest that imaging at the later time may be preferable. Prospective study of [(89)Zr]Zr-PSMA-617 PET/CT is warranted.
format Online
Article
Text
id pubmed-10317886
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103178862023-07-05 Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer Rosar, Florian Khreish, Fadi Marlowe, Robert J. Schaefer-Schuler, Andrea Burgard, Caroline Maus, Stephan Petto, Sven Bartholomä, Mark Ezziddin, Samer Eur J Nucl Med Mol Imaging Original Article RATIONALE: In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 ((89)Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions that are missed when using tracers incorporating short-lived radionuclides. MATERIALS AND METHODS: To confirm [(89)Zr]Zr-PSMA-617 positron emission tomography/computed tomography (PET/CT) detection efficacy regarding such lesions, and compare quality of 1-h, 24-h, and 48-h [(89)Zr]Zr-PSMA-617 scans, we retrospectively analyzed visual findings and PET variables reflecting lesional [(89)Zr]Zr-PSMA-617 uptake and lesion-to-background ratio. The cohort comprised 23 men with BCR post-prostatectomy, median (minimum–maximum) prostate-specific antigen (PSA) 0.54 (0.11–2.50) ng/mL, and negative [(68)Ga]Ga-PSMA-11 scans 40 ± 28 d earlier. Primary endpoints were percentages of patients with, and classifications of, suspicious lesions. RESULTS: Altogether, 18/23 patients (78%) had 36 suspicious lesions (minimum–maximum per patient: 1–4) on both 24-h and 48-h scans (n = 33 lesions) or only 48-h scans (n = 3 lesions). Only one lesion appeared on a 1-h scan. Lesions putatively represented local recurrence in 11 cases, and nodal or bone metastasis in 21 or 4 cases, respectively; 1/1 lesion was histologically confirmed as a nodal metastasis. In all 15 patients given radiotherapy based on [(89)Zr]Zr-PSMA-617 PET/CT, PSA values decreased after this treatment. Comparison of PET variables in 24-h vs 48-h scans suggested no clear superiority of either regarding radiotracer uptake, but improved lesion-to-background ratio at 48 h. CONCLUSIONS: In men with BCR and low PSA, [(89)Zr]Zr-PSMA-617 PET/CT seems effective in finding prostate malignancy not seen on [(68)Ga]Ga-PSMA-11 PET/CT. The higher detection rates and lesion-to-background ratios of 48-h scans versus 24-h scans suggest that imaging at the later time may be preferable. Prospective study of [(89)Zr]Zr-PSMA-617 PET/CT is warranted. Springer Berlin Heidelberg 2023-05-06 2023 /pmc/articles/PMC10317886/ /pubmed/37148297 http://dx.doi.org/10.1007/s00259-023-06241-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Rosar, Florian
Khreish, Fadi
Marlowe, Robert J.
Schaefer-Schuler, Andrea
Burgard, Caroline
Maus, Stephan
Petto, Sven
Bartholomä, Mark
Ezziddin, Samer
Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
title Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
title_full Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
title_fullStr Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
title_full_unstemmed Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
title_short Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
title_sort detection efficacy of [(89)zr]zr-psma-617 pet/ct in [(68)ga]ga-psma-11 pet/ct-negative biochemical recurrence of prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317886/
https://www.ncbi.nlm.nih.gov/pubmed/37148297
http://dx.doi.org/10.1007/s00259-023-06241-0
work_keys_str_mv AT rosarflorian detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT khreishfadi detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT marlowerobertj detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT schaeferschulerandrea detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT burgardcaroline detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT mausstephan detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT pettosven detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT bartholomamark detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer
AT ezziddinsamer detectionefficacyof89zrzrpsma617petctin68gagapsma11petctnegativebiochemicalrecurrenceofprostatecancer